The stock is in a short term consolidation stage. It bottomed at the end of September-17 and has been trending up in steps and has demonstrated resilience. In Q1-2018 the company is expected to announce results related to its CanaPsor014 which can propel the stock to the $2 - $3 range.
Psoriasis (Skin Disease) • Preclinical “Dead Sea Study” showed up to 70% decline of inflammatory skin disease markers and decline in proliferation of Keratocytes • Phase I safety study will be completed at Sheba Hospital, Tel Hashomer in Q1/2018 – 26 patients